for skin cancer, guardians' preferences for this early education rose significantly (P ¼ .03) to 94% (Fig 1) .
Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata To the Editor: Alopecia areata (AA) is a common and often recalcitrant condition with potentially devastating emotional and psychosocial effects. There are several case reports and series regarding the use of oral Janus kinase (JAK) inhibitors for treatment of AA and, more recently, 2 open-label clinical trials. [1] [2] [3] Oral JAK inhibitors have been associated with adverse effects including serious infections in up to 2%-6% of patients. 4 Topical formulations might offer decreased risk compared with systemic therapy. To date, there has been 1 report of a teenage girl with alopecia universalis who experienced significant hair regrowth with use of ruxolitinib 0.6% cream. 5 We report 6 pediatric AA patients treated with topical JAK inhibitors. Our findings are summarized in Table I . Topical preparations included tofacitinib and ruxolitinib creams in 1% and 2% formulations 
No response None
AA, Alopecia areata; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AT, alopecia totalis; AU, alopecia universalis; BID, twice daily; Dx, diagnosis; F, female; JAK, Janus kinase; M, male; N/A, not applicable; PMH, past medical history; QOD, every other day; SADBE, squaric acid dibutylester; WBC, white blood cell count.
prepared by a compounding pharmacy. All but one patient had previously failed multiple conventional treatments. Before initiation of therapy, baseline laboratory assessment, including complete blood count; liver enzymes; blood urea nitrogen; creatinine; and screening for tuberculosis, human immunodeficiency virus, and hepatitis viruses B and C, was performed for 4 of 6 patients. The remaining 2 patients (1 and 3) did not undergo baseline laboratory screening because they applied the cream to a limited body surface area (eyebrows), and the potential for systemic absorption was thought to be low. Followup laboratory monitoring included at a minimum complete blood count, alanine aminotransferase, blood urea nitrogen, and creatinine. Four of 6 patients demonstrated some regrowth of hair. Patient 1 had 20% regrowth of eyebrows. Patient 2 had 75% regrowth of upper eyelashes. Patients 3 and 4 had 95% and 80% regrowth of scalp hair, respectively. There were no serious adverse effects. Two patients using tofacitinib 2% cream demonstrated mild laboratory abnormalities, which could not definitively be attributed to treatment; their condition normalized after 3 months of ongoing treatment. Patient 4 had no response to topical tofacitinib 2% compounded in VersaBase cream (a nonliposomal base) but had complete hair regrowth with application of tofacitinib 2% in a liposomal base in areas of alopecia that had been persistent and stable for over 1 year (Fig 1, A and B) .
In these 6 pediatric patients, topical formulations of tofacitinib and ruxolitinib in 1%-2% concentrations were well-tolerated by all and beneficial for most. The experience of patient 4 suggests that a liposomal base, while less cosmetically elegant than VersaBase cream, might provide greater efficacy. Given that AA can resolve spontaneously, a definitive response to any treatment is difficult to assess. Additional studies will be important to elucidate patient factors that affect response to treatment, determine optimal formulation and dosing regimens, and delineate parameters for laboratory monitoring. Clinical trials exploring the use of topical JAK inhibitors for AA are presently underway (clinicaltrials. gov identifiers NCT02812342 and NCT02553330).
Topical JAK inhibitors represent a promising therapeutic option for at least a subset of patients with AA. If confirmed to be effective in clinical trials, topical administration might be preferable for certain populations, including children and patients with more limited disease. Systematic review and quality analysis of studies on the efficacy of topical diphenylcyclopropenone treatment for alopecia areata
To the Editor: Since 1983, topical diphenylcyclopropenone (DPCP) immunotherapy has been used for the treatment of alopecia areata (AA). Despite several reports showing positive results, 1,2 there are still questions about its efficacy. In this study, we aimed to evaluate the efficacy of topical DPCP treatment for AA by performing a systematic review and quality analysis of relevant articles.
The PubMed, EMBASE, and Cochrane Library databases were searched for articles published from 1983 through 2015. Retrieved articles were scored using a modified version of the quality score originally developed for randomized clinical trials (RCTs). 3 Each study had different standards of assessing the clinical response to DPCP immunotherapy. To calculate average response rate, we categorized patients according to the assessment criteria used in each of the studies. Then, the median value was calculated from the range of different response rates in the individual studies, and the overall estimated average, standard error, and 95% confidence intervals (CIs) were then calculated. All effects were computed using the Comprehensive Meta-Analysis version 2.2.064 software (Biostat, Englewood, NJ).
Of the 26 studies included in the final analysis ( Supplementary Fig 1; available at http://www.jaad. org), 5 studies enrolled #20 patients, 7 studies enrolled 21-40 patients, and 14 studies enrolled [40 patients. Seventeen studies had no information regarding controls, 3 involved the use of parallel concurrent controls, and 6 were self-controlled trials. None were randomized, blinded, or RCTs. The results of quality analysis of individual items are reported in Table I .
The average response rate of DPCP treatment in 26 studies was 53.75% 6 0.79% (95% CI 52.20%-55.30%; Fig 1) . The average response rate of DPCP treatment for alopecia totalis (AT) and alopecia universalis (AU) was 47.65% 6 1.69% (95% CI 44.34%-50.96%) when considering the 9 studies that separately analyzed the results of patients with AT and AU. Although little is known about the natural course of AA, at least 50% of patients with patchy AA \1 year experienced spontaneous remission. 4 However, in extensive AA, such as AT and AU, the chance of full recovery is \10%. 5 The types of adverse events caused by DPCP treatment were recorded in 15 articles representing a total of 800 patients. The common adverse events included extensive eczematous reaction of the scalp (20.8%), occipital or cervical lymphadenopathy (13.5%), disseminated contact eczema (8.5%), hyperpigmentation (6.8%), severe generalized itching (6.4%), hypopigmentation (1.6%), and others (eg, erythema multiforme-like reaction, urticaria; 1.3%).
There were several potential limitations to this study. First, the search was restricted to articles written in the English language. Second, the relative advantage of DPCP over placebo was not clear because most studies did not have a control group. Third, because different alopecia scoring systems were used in different studies, combining the data was challenging and required some approximations. To minimize this problem in future studies, use of a standardized scoring tool, such as Severity of Alopecia Tool, is advisable.
In conclusion, we found evidence to support the efficacy of topical immunotherapy with DPCP for AA. However, better designed RCTs with a clinically relevant endpoint (eg, long-term overall regrowth) and a well-selected population are essential.
